VO and Nivolumab vs Physician ' s Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

Conditions: Advanced Melanoma Interventions: Biological: Vusolimogene Oderparepvec; Biological: Nivolumab; Biological: Nivolumab + Relatlimab; Biological: Pembrolizumab; Drug: Single-agent chemotherapy Sponsors: Replimune Inc. Not yet recruiting

https://clinicaltrials.gov/study/NCT06264180

Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials

More News: Chemotherapy | Melanoma | Research | Skin Cancer